Rapport Therapeutics’ Lock-Up Period Will Expire on December 4th (NASDAQ:RAPP)

Rapport Therapeutics’ (NASDAQ:RAPP) lock-up period is set to end on Wednesday, December 4th. Rapport Therapeutics had issued 8,000,000 shares in its IPO on June 7th. The total size of the offering was $136,000,000 based on an initial share price of $17.00. After the end of the company’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Rapport Therapeutics Stock Up 0.0 %

Rapport Therapeutics stock opened at $22.34 on Wednesday. Rapport Therapeutics has a 12-month low of $16.55 and a 12-month high of $29.74. The business has a 50 day moving average price of $23.01.

Institutional Investors Weigh In On Rapport Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Values First Advisors Inc. purchased a new position in Rapport Therapeutics in the 3rd quarter worth approximately $31,000. BNP Paribas Financial Markets purchased a new position in shares of Rapport Therapeutics in the third quarter worth $34,000. SG Americas Securities LLC bought a new position in shares of Rapport Therapeutics during the third quarter worth $101,000. Sandia Investment Management LP purchased a new position in Rapport Therapeutics during the second quarter valued at $116,000. Finally, MetLife Investment Management LLC bought a new stake in Rapport Therapeutics in the 3rd quarter valued at $117,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.